Lantern Pharma Partners with IBN to Enhance Corporate Communications Amidst AI-Driven Oncology Advancements

Lantern Pharma, a biotechnology company listed on NASDAQ under the ticker LTRN, has entered into a strategic partnership with IBN to bolster its corporate communications efforts. This move is timed with the company's significant strides in developing precision oncology drugs through its proprietary RADR(R) AI platform. Lantern Pharma's focus encompasses a broad spectrum of cancers, including lung, brain, breast, and blood cancers, with three AI-guided drug candidates currently under development and a dedicated subsidiary for central nervous system (CNS) therapies.

The collaboration with IBN is designed to enhance investor awareness regarding Lantern Pharma's cutting-edge approach to oncology drug development. The RADR(R) platform stands at the core of the company's innovation, harnessing over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms. This technological prowess has significantly reduced the time and cost associated with bringing new therapies to clinical trials, with first-in-human trials achieved in just 2-3 years at an average cost of $2.5 million per program.

Currently, Lantern Pharma is actively conducting trials for several therapies that have received FDA designations, highlighting its commitment to transforming cancer treatment through artificial intelligence and machine learning. For further insights into Lantern Pharma's pioneering work and its partnership with IBN, interested parties can visit https://ibn.fm/6gYcX. Additional updates and information about the company's endeavors are available in its newsroom at https://ibn.fm/LTRN.